Chinese medicinal composition for treating pulmonary fibrosis and its application

A technology for pulmonary fibrosis and composition, which is applied in the field of traditional Chinese medicine compositions for the treatment of pulmonary fibrosis, and can solve the problems of no improvement in X-ray chest films and the like

Active Publication Date: 2013-03-13
ZHEJIANG UNIV
View PDF3 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The records of traditional Chinese medicine treatment of silicosis mention that Bletilla striata has a therapeutic effect on the symptoms of silicosis, but it does not improve the X-ray chest film

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chinese medicinal composition for treating pulmonary fibrosis and its application
  • Chinese medicinal composition for treating pulmonary fibrosis and its application
  • Chinese medicinal composition for treating pulmonary fibrosis and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] 1.1 Experimental animals, drugs, reagents and instruments

[0026] ICR mice, male, 8 weeks old, weighing 20-22 g, provided by the Animal Experiment Center of Zhejiang University, animal certificate number: 2007000526749. The animal feeding and operation process complied with the requirements of the "Regulations on the Administration of Experimental Animals" of Zhejiang University. Bleomycin: Sigma, batch number: 9041-93-4; dexamethasone sodium phosphate injection (Zhejiang Xianju Pharmaceutical Co., Ltd.); Real time PCR related reagents (including dNTP Mixture, Oligo(dt)18primer, RNase Inhibitor , M-MLV Reverse Transcriptase): Treasure Bioengineering (Dalian) Co., Ltd.; hydroxyproline assay kit: KGT030-2; mouse TGF-β1 ELISA kit: Wuhan Boster Bioengineering Co., Ltd.; mouse β-actin and PDE8A primers were synthesized by Shanghai Sangon Bioengineering Co., Ltd.; PCR instrument: Eppendoff Company; horizontal electrophoresis instrument: British CLP Company.

[0027] Tradit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a Chinese medicinal composition for treating pulmonary fibrosis and its application. The Chinese medicinal composition consists of the following components by weight: 3.6-4 parts of Bletilla striata, 0.9-1.2 parts of Galla Chinensis, 1-1.2 parts of Bombyx Batryticatus, 4-4.5 parts of rhizoma atractylodis macrocephalae, 4-5 parts of Adenophora elata, 4-4.5 parts of Radix Stemonae, 1-1.2 parts of platycodon grandiflorum, and 7-8 parts of codonopsis pilosula. Research shows that the aqueous extract of the Chinese medicinal composition provided in the invention has an obvious inhibiting effect on a pulmonary fibrosis animal model TGF beta, and the composition can be used for preparing anti-pulmonary fibrosis drugs. In the invention, new application and treatment mechanism of the Chinese medicinal composition are developed. The Chinese medicinal composition is in favor of studying the pulmonary fibrosis mechanism and treatment drugs, and provides an experimental foundation for new drugs treating pulmonary fibrosis.

Description

1. Technical field [0001] The invention relates to a traditional Chinese medicine composition for treating pulmonary fibrosis and its application. 2. Background technology [0002] Pulmonary fibrosis (IPF) is a disease of unknown cause, characterized by diffuse alveolitis and alveolar structural disorder, which eventually leads to pulmonary interstitial fibrosis. It is the final outcome of many pulmonary interstitial diseases. The main pathological feature is the mixed presence of fibrosis and inflammatory cell infiltration in the pulmonary interstitium and alveolar cavity. As far as its anatomical location is concerned, although it occurs in the pulmonary interstitial system, it usually affects the alveoli and bronchi. As far as its etiology is concerned, it is a lung disease caused by multiple factors such as inflammation, infection, allergy, immunity, granuloma, tumor, hyperplasia, and obstruction. The current therapeutic drugs are mainly glucocorticoids, immunosuppres...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/904A61P11/00A61K35/64
Inventor 汤慧芳危金松李子刚李金优曾豆豆
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap